


SL-11. MDM2-p53

MDM2/p53 is a protein-protein interaction (PPI) which regulates a variety of cellular pathways involved in the onset and development of cancer. MDM2 is a negative regulator of tumor suppression protein p53 thus making MDM2 an attractive target for anticancer therapeutics. Structurally MDM2 has several deep hydrophobic binding pockets that fit α-helical p53. Therefore, synthetic small molecule alpha-helix mimetic scaffolds provide a very promising strategy for designing inhibitors of MDM2 and other α-helix mediated PPIs. At ASINEX, we performed *in silico* analyses of common structural futures of known MDM2 antagonists to build up a predictive pharmacophore model [1]. Several αhelix mimetic scaffolds were selected as p53 backbone mimetics and p53 binding epitope mimetics [2,3]. The *in vitro* potency of compounds was confirmed in a fluorescence polarization assay, with the IC50s ranging from 1 to 10 µM.



Signature Library 11

Formats	Supplementary Information
80 compounds per plate	IC ₅₀ [Mdm2/p53]
0.1 mg; 1 mg; 2 mg dry film/powder	Solubility data in PBS
0.1 µmol; 1 µmol DMSO solutions	SL#11_MDM2_p53_05-16.sdf

References:

- 1. J Med Chem. 2015 Feb 12;58(3):1038-52. doi: 10.1021/jm501092z
- 2. Med. Chem. Commun., 2013, 4, 1597-1603 doi: 10.1039/C3MD00211J
- 3. Chem Biol Drug Des. 2014 Nov;84(5):585-92. doi: 10.1111/cbdd.12351

<u>Contact us</u>: USA: Japan: Europe/Global:

+1 336 721 1617 +81-80-3401-9097

mparisi@asinex.com sota@asinex.com lsadovenko@asinex.com

asinex.com